Critical Path Institute (C-Path)

▶New Impact Story◀ How C-Path's Biomarker Data Repository Brings Patients to the Table to Discuss Biomarkers and Their Impact   BmDR’s work embodies C-Path’s mission to lead collaborations that accelerate drug development and advance better treatments for people worldwide. C-Path generates solutions to facilitate scientific and regulatory pathways that accelerate the development of therapies for people with unmet medical needs. C-Path doesn’t develop therapies; C-Path accelerates their development, helps them get to market faster, and helps improve patients’ lives. At a recent BmDR Community Engagement Committee meeting, Dave White detailed the frustrations patients face when treatments take too long to become available. “This takes me back to 2017 when I was with the Kidney Health Initiative, and we were in the midst of co-creating the Kidney Health Initiative’s renal replacement therapy roadmap. One of the Patient Advisory Committee members became so frustrated that she quit because she couldn’t understand why it took so long to be cured and have adequate treatments. We, as a team, didn’t really know how to explain it either. That would have been the perfect time to explain the BmDR  and what we are trying to develop.” To read more of this impact story, click here: https://lnkd.in/gdin2H29 Glenda V. Roberts, Dave White, Richard Knight, MBA #CPath #DrugDevelopment #Collaboration #PatientFocused #Biomarkers #KidneyDiease #CommunityEngagement #PatientEngagement

C-Path is proud to share Vice President of Neurology Diane Stephenson’s insightful post below and extend our heartfelt congratulations to Diane and all the co-authors of this pioneering manuscript, “Accelerating Parkinson’s Disease Drug Development with Federated Learning.” This publication represents a significant step forward in leveraging federated machine learning to enhance collaboration, maintain patient privacy, and accelerate treatment development for Parkinson’s disease. At the core of this effort is a commitment to innovation and global teamwork — a commitment that Diane so eloquently celebrates in her post. We are inspired by the collaboration between Diane Stephenson, Novartis leaders Amit Khanna, GRAHAM JONES, Laura Gaetano, and the entire team, as well as Diane’s call to action in honor of Carl Ames, a champion for digital health technologies in the fight against PD. Join us in acknowledging the power of partnership in advancing solutions for Parkinson’s disease. Open access to the manuscript here: https://lnkd.in/g3H_KEcW #CPath #ParkinsonsDisease #DrugDevelopment #DigitalHealth #DataSharing #Collaboration

C-Path's Jagdeep Podichetty, PhD, and Nick Henscheid, presented on Fundamentals of Data Science and Machine Learning as part of the Fall 2024 CTS 641A course in the Clinical Translational Sciences Graduate Program at the University of Arizona. The presentation provided an overview of AI/ML principles and their applications in healthcare and drug development. This session highlighted the transformative role of machine learning in advancing medical research and patient care, with a practical focus on building an XGBoost Classification Model to predict breast cancer recurrence. Students gained foundational knowledge and hands-on experience with tools that are shaping the future of healthcare innovation. #CPath #DrugDevelopment #MachineLearning #AI #ML #Collaboration

The Tucson community is special. Known to be welcoming, C-Path has had the unwavering support of our local partners since our doors first opened in 2005. At C-Path, our engagement with the community goes hand-in-hand with fulfilling our mission. By forging deep connections, we can achieve our mission to lead collaborations that accelerate drug development more effectively and create positive, lasting change. This weekend, C-Pathians participated in one of the city’s most celebrated events, the 41st Perimeter Bicycling - El Tour de Tucson, the renowned cycling race that draws participants from all over the globe. C-Path’s involvement with El Tour kicked off in 2013 and the team has sent riders every year since. As C-Path has grown, so too have the number of C-Pathians and their families that come out to join the other 9,000 cyclists. This year’s event was held this past Saturday, November 23, 2024. The weather was an ideal 76 degrees with partly cloudy skies, and a nice breeze making it the perfect day for a Saturday ride. Thanks to all who participated in this Tucson favorite. Nicholas King, Diane Stephenson, Christine Miller, Ramona Walls, Kristen Swingle, Maaike Everts, Michael Pauley #Tucson #CPath #Collaboration #DrugDevelopment #ElTourdeTucson

Upcoming webinar: The Power of Data Sharing and Collaboration Across LGMDs in a Pre-Competitive, Neutral Environment 📅 Thursday, December 12 | 11 AM ET This event will feature Dr. Volker Straub, a renowned neuromuscular genetics expert and Director of the John Walton Muscular Dystrophy Research Centre @ Newcastle University. Dr. Straub will provide an overview of Limb-Girdle Muscular Dystrophies and highlight critical unmet needs in the field. He’ll be joined by a panel of experts: Douglas Sproule (ML Bio Solutions) Jennifer Levy (Coalition to Cure Calpain 3) Kat Bryant Knudson (Speak Foundation) Sophie Olivier (Atamyo Therapeutics) Cécile Ollivier (C-Path) Together, they’ll explore how the launch of the LGMDs Task Force aims to foster data sharing across LGMD subtypes, drive innovation in drug development, and inspire new researchers to enter the field. What you'll gain: ▶ Learn about cutting-edge initiatives to address challenges in LGMD research. ▶Hear diverse perspectives from advocacy leaders, industry stakeholders, and leading scientists. ▶Discover how collaboration in a pre-competitive, neutral environment can accelerate progress for LGMDs. Don’t miss this opportunity to be part of a conversation that could shape the future of LGMD drug development. 🔗 Register now: https://lnkd.in/d5EkhkPT Collin Hovinga Alexandre Bétourné, PhD, PharmD, PMP Ramona Belfiore-Oshan Heidi Grabenstatter #CPath #RareDisease #LGMD #limbgirdle #musculardystrophy #drugdevelopment #datasharing #collaboration #taskforce #globalhealth

Have questions about C-Path's mission? Whether you’re curious about how we collaborate with stakeholders, or how we’re accelerating the development of new treatments, our FAQs section is a valuable resource designed to give you the insights you need. Have a question we haven’t answered yet? Don’t hesitate to reach out—we’re always here to help and provide guidance. You can find more questions and answers on C-Path's website under FAQS: c-path.org/faqs. #C-Path #FAQs #DrugDevelopment

Have questions about how C-Path’s works? Whether you’re curious about how we collaborate with stakeholders, or how we’re accelerating the development of new treatments, our FAQs section is a valuable resource designed to give you the insights you need. Have a question we haven’t answered yet? Don’t hesitate to reach out—we’re always here to help and provide guidance. You can find more questions and answers on C-Path's website under FAQS: c-path.org/faqs. #C-Path #FAQs #DrugDevelopment

C-Path’s Critical Path for Alzheimer Disease (CPAD) Consortium is using advanced analytical techniques to transform patient-level information into quantitative knowledge which is actionable. The large CPAD database of patient-level clinical trial data is used to develop quantitative disease, drug, and trial models that can answer the design-related clinical study questions (e.g. duration of study, optimal timing of assessments), thereby accelerating decision making and getting effective treatments to patients faster.  Discover how C-Path is pioneering advancements in quantitative modeling for Alzheimer’s disease by visiting c-path.org/cpad.  #CPath #AlzheimersDiseaseAwarenessMonth #CPAD #Biomarkers #PatientVoice

Watch now: Executive Director of C-Path's Duchenne Regulatory Science Consortium, Ramona Belfiore-Oshan and Quantitative Medicine Director, Luke Kosinsksi, moderated the panel discussion, "Identifying and Quantifying Sources of Variability." Leveraging real-world data enhances trial design by understanding variability and improving patient outcomes in drug development. https://lnkd.in/gctXxFuP #CPath #Variability #PatientOutcomes #DrugDevelopment

Interested in C-Path updates? Be sure to subscribe at https://lnkd.in/gmicc5Ay For 20 years, C-Path has been providing vital infrastructure to generate a neutral environment for everyone working in drug development to collaborate, not compete. Let's improve lives, together. #CPath #drugdevelopment #neutral #datasharing #globalhealth #collaboration #regulatoryscience